Xiao-Dan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiao-Dan Zhang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Jia-Lie Luo
School of Pharmacy, Nantong University, No. 9, Seyuan Road, Nantong 226001, China
2 shared publications - Liyun Wang
School of Pharmacy, Nantong University, No. 9, Seyuan Road, Nantong 226001, China
2 shared publications - Qing Zhu
School of Pharmacy Nantong University Nantong Jiangsu China
2 shared publications - Han Wang
Nantong First People's Hospital, Affiliated Hospital 2 of Nantong University, Nantong Hospital of Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Southeast University Affiliated Nantong First People's Hospital, No. 666 Shengli Road, Chongchuan District, Nantong, Jiangsu Province 226000, China
1 shared publication - Jianhua Shi
Institute for Translational Neuroscience, Second Affiliated Hospital, Nantong University, Nantong 226001, China
1 shared publication - Jiejia Li
School of Pharmacy, Nantong University, No. 9, Seyuan Road, Nantong 226001, China
1 shared publication
Latest Publications
- Open Access
- 8 September 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (9) , 1290
Translating Alzheimer’s Disease Mechanisms into Therapeutic Opportunities
Alzheimer’s disease (AD), characterized by progressive cognitive decline and functional impairment, is the most prevalent cause of dementia, and it poses a significant socioeconomic and caregiving burden on patients, families, and healthcare systems. Notwithstanding comprehensive research, the precise causes underlying AD remain ambiguous. Evidence increasingly indicates that AD is a multifactorial and heterogeneous disease involving a mix of genetic and environmental factors. The amyloid-cascade hypothesis, neuroinflammation and immunity, vascular pathology, and oxidative stress all fulfill significant functions in the onset and development of AD. This review primarily examines the critical pathogenesis, key biomarkers, and novel therapeutic strategies of Alzheimer’s disease to inform future research directions.
- 8 September 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (9) , 1290
Open AccessTranslating Alzheimer’s Disease Mechanisms into Therapeutic Opportunities
Alzheimer’s disease (AD), characterized by progressive cognitive decline and functional impairment, is the most prevalent cause of dementia, and it poses a significant socioeconomic and caregiving burden on patients, families, and healthcare systems. Notwithstanding comprehensive research, the precise causes underlying AD remain ambiguous. Evidence increasingly indicates that AD is a multifactorial and heterogeneous disease involving a mix of genetic and environmental factors. The amyloid-cascade hypothesis, neuroinflammation and immunity, vascular pathology, and oxidative stress all fulfill significant functions in the onset and development of AD. This review primarily examines the critical pathogenesis, key biomarkers, and novel therapeutic strategies of Alzheimer’s disease to inform future research directions.
- Open Access
- 19 May 2023
- Published by MDPI AG in Preprints.org
GABA Receptor Subtypes Involvement of Analgesia: Current Status
Gamma-aminobutyric acid (GABA), a non-protein-producing amino acid, is extensively found in microorganisms, plants and vertebrates, and is abundantly expressed in the spinal cord and brain. To date, GABA is considered to be the major inhibitory neurotransmitter in the central nervous system. Its physiological effects are related to the regulation of synaptic transmission, the promotion of neuronal development and relaxation, and the prevention of insomnia and depres-sion. Mediated through its specific receptors, it plays a pivotal role in the control of neuronal ex-citability, which can serve as anovel target for developing analgesics for pain management. This review provides an update on the accumulating evidence of specific GABA receptors and their subtypes in the involvement of pain analgesia.
- 19 May 2023
- Published by MDPI AG in Preprints.org
Open AccessGABA Receptor Subtypes Involvement of Analgesia: Current Status
Gamma-aminobutyric acid (GABA), a non-protein-producing amino acid, is extensively found in microorganisms, plants and vertebrates, and is abundantly expressed in the spinal cord and brain. To date, GABA is considered to be the major inhibitory neurotransmitter in the central nervous system. Its physiological effects are related to the regulation of synaptic transmission, the promotion of neuronal development and relaxation, and the prevention of insomnia and depres-sion. Mediated through its specific receptors, it plays a pivotal role in the control of neuronal ex-citability, which can serve as anovel target for developing analgesics for pain management. This review provides an update on the accumulating evidence of specific GABA receptors and their subtypes in the involvement of pain analgesia.